Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Clinical trial NCT06817720 · RECRUITING
Trial details
- NCT number
- NCT06817720
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-13
- Primary completion
- 2027-03-07
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.